1. Academic Validation
  2. Tetrazole hybrids with potential anticancer activity

Tetrazole hybrids with potential anticancer activity

  • Eur J Med Chem. 2019 Sep 15:178:341-351. doi: 10.1016/j.ejmech.2019.05.071.
Jingyu Zhang 1 Su Wang 2 Yanyan Ba 2 Zhi Xu 3
Affiliations

Affiliations

  • 1 Pharmacy College, Henan University of Chinese Medicine, 450046, Zhengzhou, PR China. Electronic address: jyzhang2004@126.com.
  • 2 Pharmacy College, Henan University of Chinese Medicine, 450046, Zhengzhou, PR China.
  • 3 Huanghuai University, College of Chemistry and Pharmaceutical Engineering, Zhumadian, PR China. Electronic address: chemorgchem@126.com.
Abstract

Cancer is one of the main causes of death throughout the world. The Anticancer agents are indispensable for the treatment of various cancers, but most of them currently on the market are not specific, resulting in series of side effects of chemotherapy. Moreover, the emergency of drug-resistance towards cancers has already increased up to alarming level in the recent decades. Therefore, it's imperative to develop novel Anticancer candidates with excellent activity against both drug-susceptible and drug-resistant cancers, and low toxicity as well. Tetrazole is the bioisoster of carboxylic acid, and its derivatives demonstrated promising Anticancer activity. Hybridization of tetrazole with other Anticancer pharmacophores may provide novel candidates with Anticancer potency. The present review described the Anticancer activity of tetrazole hybrids, and the structure-activity relationship (SAR) is also discussed to provide an insight for rational designs of tetrazole Anticancer candidates with higher efficiency.

Keywords

Anticancer activity; Hybrid compounds; Structure-activity relationship; Tetrazole.

Figures